Rasheed A. Gbadegesin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rasheed A. Gbadegesin has a total of 671 co-authors. Here are the top co-authors by number of shared publications:
Guanghong Wu
Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA; Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina, USA
15 shared publicationsGentzon Hall
Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina
11 shared publications- Adebowale Adeyemo
Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, USA
7 shared publications Alison Homstad
Department of Pediatrics, Duke University Medical Center, Durham, USA
7 shared publicationsBrandon M. Lane
Department of Pediatrics, Division of Nephrology, Duke University Medical Center, Durham, NC, United States
7 shared publications- Brandon M. Lane
Department of Pediatrics, Division of Nephrology, Duke University, Durham, NC; Duke Molecular Physiology Institute, Duke University, Durham, NC
7 shared publications
Latest Publications
- 20 July 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (9) , 1852-1854
Elucidating Therapeutic Targets in Hereditary Multicentric Carpotarsal Osteolysis FSGS
Was not provided for this article.
- 20 July 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (9) , 1852-1854
Elucidating Therapeutic Targets in Hereditary Multicentric Carpotarsal Osteolysis FSGS
Was not provided for this article.
- 23 June 2026
- Published by Elsevier in Advances in Kidney Disease and Health
- Vol. 33 (1) , 48-70
Genetic Nephrotic Syndrome in Children and Adolescents: An Update
- 23 June 2026
- Published by Elsevier in Advances in Kidney Disease and Health
- Vol. 33 (1) , 48-70
Genetic Nephrotic Syndrome in Children and Adolescents: An Update
- 5 June 2026
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (11) , 3813-3826
Update on APOL1 and chronic kidney diseases in children
Chronic kidney disease (CKD) is a major global health burden that disproportionately impacts people of recent African ancestry. The discovery of risk variants in the apolipoprotein L1 (APOL1) gene has transformed the understanding of racial disparities in CKD. In particular, APOL1 variants have been associated with increased risk of focal segmental glomerulosclerosis, virus-associated nephropathy, and other glomerular diseases in Black adults. While approximately 10-15% of Black Americans have a high-risk APOL1 genotype, disease penetrance is variable and is likely mediated by additional genetic and environmental "second hits." Variants in APOL1 have also been implicated in kidney transplant outcomes and pregnancy complications, underscoring its broad clinical relevance. Advances in therapeutic strategies, including small molecule inhibitors of APOL1 pore function, APOL1 antisense oligonucleotides, and JAK-STAT pathway modulation, offer promise for targeted interventions in adult populations. Emerging data in children highlight similar genotype-phenotype associations, with evidence of high-risk APOL1 genotype impacting steroid-resistant nephrotic syndrome and CKD progression. However, pediatric studies remain limited and underpowered, leaving critical gaps in the understanding of disease epidemiology, mechanisms, and long-term outcomes. This review will explore current knowledge of APOL1 kidney disease (AMKD) with a particular focus on pediatric populations and highlight the need for inclusion of children in future studies.
- 5 June 2026
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (11) , 3813-3826
Update on APOL1 and chronic kidney diseases in children
Chronic kidney disease (CKD) is a major global health burden that disproportionately impacts people of recent African ancestry. The discovery of risk variants in the apolipoprotein L1 (APOL1) gene has transformed the understanding of racial disparities in CKD. In particular, APOL1 variants have been associated with increased risk of focal segmental glomerulosclerosis, virus-associated nephropathy, and other glomerular diseases in Black adults. While approximately 10-15% of Black Americans have a high-risk APOL1 genotype, disease penetrance is variable and is likely mediated by additional genetic and environmental "second hits." Variants in APOL1 have also been implicated in kidney transplant outcomes and pregnancy complications, underscoring its broad clinical relevance. Advances in therapeutic strategies, including small molecule inhibitors of APOL1 pore function, APOL1 antisense oligonucleotides, and JAK-STAT pathway modulation, offer promise for targeted interventions in adult populations. Emerging data in children highlight similar genotype-phenotype associations, with evidence of high-risk APOL1 genotype impacting steroid-resistant nephrotic syndrome and CKD progression. However, pediatric studies remain limited and underpowered, leaving critical gaps in the understanding of disease epidemiology, mechanisms, and long-term outcomes. This review will explore current knowledge of APOL1 kidney disease (AMKD) with a particular focus on pediatric populations and highlight the need for inclusion of children in future studies.
- Open Access
- 15 May 2026
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 40
Food Insecurity and Blood Pressure in West Africans with Chronic Kidney Disease
- 15 May 2026
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 40
Open AccessFood Insecurity and Blood Pressure in West Africans with Chronic Kidney Disease
- Open Access
- 24 February 2026
- Published by Elsevier in Kidney International
- Vol. 109 (6) , 1256-1268
Polygenic risk scores and HLA class II variants are biomarkers of corticosteroid response in childhood nephrotic syndrome
- 24 February 2026
- Published by Elsevier in Kidney International
- Vol. 109 (6) , 1256-1268
Open AccessPolygenic risk scores and HLA class II variants are biomarkers of corticosteroid response in childhood nephrotic syndrome
- 17 February 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (11) , 2041-2050
National Institutes of Health Workshop to Accelerate Therapeutic Innovation by Optimizing Kidney Precision Medicine Clinical Trials
The National Institute of Diabetes and Digestive and Kidney Diseases sponsored a scientific workshop in 2024, titled “Preparing for Kidney Precision Medicine Clinical Trials.” The purpose of the workshop was to gain a better understanding of the therapeutic journey of patients with kidney disease and define candidate indicators for precision medicine strategies, targets, and trial readiness. Workshop participants were tasked with identifying best practices, opportunities, and barriers to kidney precision medicine clinical trials, with a shared goal to optimize the design and conduct of these trials. The patient perspective served as a foundation for the meeting. Trial design should be flexible, dynamic, responsive to transitions in patient care and minimize fragmentation of care. The value of understanding mechanisms and defining endophenotypes and targets to facilitate new therapeutic approaches was discussed with examples presented for acute and CKDs. The importance of biomarkers for diagnosis and evaluation of therapeutic response was emphasized. Laboratory and assay considerations for precision medicine trials were discussed with examples of successful large precision medicine trials supported by laboratory networks presented. There was discussion of the barriers to precision trials in nephrology, including suboptimal patient engagement, precision trial expertise, infrastructure, and financial resources. Engagement in demonstration projects to test the ability of various approaches to expedite the right treatment to the right patient was highlighted. Of utmost importance is the better design of clinical trials which consider differences in genetics and status of disease mechanisms to validate individual patient-focused innovative and effective precision therapeutic approaches.
- 17 February 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (11) , 2041-2050
National Institutes of Health Workshop to Accelerate Therapeutic Innovation by Optimizing Kidney Precision Medicine Clinical Trials
The National Institute of Diabetes and Digestive and Kidney Diseases sponsored a scientific workshop in 2024, titled “Preparing for Kidney Precision Medicine Clinical Trials.” The purpose of the workshop was to gain a better understanding of the therapeutic journey of patients with kidney disease and define candidate indicators for precision medicine strategies, targets, and trial readiness. Workshop participants were tasked with identifying best practices, opportunities, and barriers to kidney precision medicine clinical trials, with a shared goal to optimize the design and conduct of these trials. The patient perspective served as a foundation for the meeting. Trial design should be flexible, dynamic, responsive to transitions in patient care and minimize fragmentation of care. The value of understanding mechanisms and defining endophenotypes and targets to facilitate new therapeutic approaches was discussed with examples presented for acute and CKDs. The importance of biomarkers for diagnosis and evaluation of therapeutic response was emphasized. Laboratory and assay considerations for precision medicine trials were discussed with examples of successful large precision medicine trials supported by laboratory networks presented. There was discussion of the barriers to precision trials in nephrology, including suboptimal patient engagement, precision trial expertise, infrastructure, and financial resources. Engagement in demonstration projects to test the ability of various approaches to expedite the right treatment to the right patient was highlighted. Of utmost importance is the better design of clinical trials which consider differences in genetics and status of disease mechanisms to validate individual patient-focused innovative and effective precision therapeutic approaches.
- 21 January 2026
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 87 (2) , 141-152
KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children
- 21 January 2026
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 87 (2) , 141-152
KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children
- 31 December 2025
- Published by Elsevier in Kidney International
- Vol. 109 (4) , 750-764
Nephrotic syndrome genomic discovery in the Mass General Brigham Biobank identifies monoallelic MEFV variants as a risk factor for focal segmental glomerulosclerosis
- 31 December 2025
- Published by Elsevier in Kidney International
- Vol. 109 (4) , 750-764
Nephrotic syndrome genomic discovery in the Mass General Brigham Biobank identifies monoallelic MEFV variants as a risk factor for focal segmental glomerulosclerosis
- Open Access
- 27 November 2025
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 9 (1) , e259
Supporting students from underrepresented minority backgrounds in graduate school: A mixed-methods formative study to inform post-baccalaureate design – ADDENDUM
- 27 November 2025
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 9 (1) , e259
Open AccessSupporting students from underrepresented minority backgrounds in graduate school: A mixed-methods formative study to inform post-baccalaureate design – ADDENDUM
- Open Access
Polygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome
Introduction: Nephrotic syndrome (NS), a common glomerular disease in children, is classified based on response to corticosteroid therapy as either steroid-sensitive nephrotic syndrome (SSNS), or steroid-resistant nephrotic syndrome (SRNS). However, there are currently no reliable predictors of therapy response at initial clinical presentation. Methods: We conducted genome-wide association studies, developed polygenic risk scores (PRS) for therapy response and analyzed classical HLA alleles in 1,997 (994 discovery and 1,003 replication/validation cohorts) previously unstudied children with NS and 3,558 ancestry-matched controls. Results: A significant association with HLA loci defined by variants in HLA-DQB1, HLA-DRB1 , and HLA-DQA1 were found for SSNS (but not SRNS), along with a second immune-related SSNS locus: CLEC16A . A PRS that discriminates between SSNS and SRNS was validated in two independent cohorts. The HLA haplotype HLA-DRB1*07:01∼DQA1*02:01∼DQB1*02:02 was associated with ∼4 times the risk of developing SSNS. A model incorporating HLA haplotype, PRS score, and age at onset of the disease was the best predictor of steroid responsiveness with an AUC of 0.68-0.70 and an overall classification accuracy of SSNS versus SRNS of 67-71%. Conclusions: Our findings confirm that SSNS (unlike SRNS) is an immune-mediated HLA-associated disorder. The PRS for therapy response and HLA haplotype can serve as biomarkers and provide a foundation for more accurate diagnoses and tailored and individualized treatment. Translational statement: To identify biomarkers of pattern of steroid responsiveness in childhood-onset nephrotic syndrome, we carried out a case-control study that included over 4,000 samples, including 994 patients with NS in the discovery phase and an additional 1,003 cases from two independent replication cohorts. We identified significant risk of steroid-sensitive NS (SSNS) at HLA class II genes and CLEC16A (a gene important in the regulation of T and B lymphocytes). The HLA haplotype DRB1*07:01∼DQA1*02:01∼DQB1*02:02 was associated with four-fold increased odds of SSNS. A model incorporating HLA haplotype, polygenic risk score, and age at onset of the disease was the best predictor of steroid responsiveness providing useful delineation of steroid sensitivity from steroid resistance. In conclusion, age at onset of disease, HLA class II variants and polygenic risk scores are useful biomarkers of corticosteroid response in childhood NS and may serve as useful clinical decision support tools to guide treatment. Abstract Figure: Graphical Abstract
Open AccessPolygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome
Introduction: Nephrotic syndrome (NS), a common glomerular disease in children, is classified based on response to corticosteroid therapy as either steroid-sensitive nephrotic syndrome (SSNS), or steroid-resistant nephrotic syndrome (SRNS). However, there are currently no reliable predictors of therapy response at initial clinical presentation. Methods: We conducted genome-wide association studies, developed polygenic risk scores (PRS) for therapy response and analyzed classical HLA alleles in 1,997 (994 discovery and 1,003 replication/validation cohorts) previously unstudied children with NS and 3,558 ancestry-matched controls. Results: A significant association with HLA loci defined by variants in HLA-DQB1, HLA-DRB1 , and HLA-DQA1 were found for SSNS (but not SRNS), along with a second immune-related SSNS locus: CLEC16A . A PRS that discriminates between SSNS and SRNS was validated in two independent cohorts. The HLA haplotype HLA-DRB1*07:01∼DQA1*02:01∼DQB1*02:02 was associated with ∼4 times the risk of developing SSNS. A model incorporating HLA haplotype, PRS score, and age at onset of the disease was the best predictor of steroid responsiveness with an AUC of 0.68-0.70 and an overall classification accuracy of SSNS versus SRNS of 67-71%. Conclusions: Our findings confirm that SSNS (unlike SRNS) is an immune-mediated HLA-associated disorder. The PRS for therapy response and HLA haplotype can serve as biomarkers and provide a foundation for more accurate diagnoses and tailored and individualized treatment. Translational statement: To identify biomarkers of pattern of steroid responsiveness in childhood-onset nephrotic syndrome, we carried out a case-control study that included over 4,000 samples, including 994 patients with NS in the discovery phase and an additional 1,003 cases from two independent replication cohorts. We identified significant risk of steroid-sensitive NS (SSNS) at HLA class II genes and CLEC16A (a gene important in the regulation of T and B lymphocytes). The HLA haplotype DRB1*07:01∼DQA1*02:01∼DQB1*02:02 was associated with four-fold increased odds of SSNS. A model incorporating HLA haplotype, polygenic risk score, and age at onset of the disease was the best predictor of steroid responsiveness providing useful delineation of steroid sensitivity from steroid resistance. In conclusion, age at onset of disease, HLA class II variants and polygenic risk scores are useful biomarkers of corticosteroid response in childhood NS and may serve as useful clinical decision support tools to guide treatment. Abstract Figure: Graphical Abstract